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ABSTRACT

The Effects of Two Novel Anti-Inflammatory
Compounds On Prepulse Inhibition and Neural Microglia
Cell Activation in a Rodent Model of Schizophrenia

by
Heath Walker Shelton

Recent studies have shown elevated neuroinflammation in a large subset of individuals
diagnosed with schizophrenia. A pro-inflammatory cytokine, tumor necrosis factor-alpha
(TNFα), has been directly linked to this neuroinflammation. This study examined the effects of
two TNFα modulators (PD2024 and PD340) produced by our collaborators at P2D Bioscience,
Inc., to alleviate auditory sensorimotor gating deficits and reduce microglial cell activation
present in the polyinosinic:polycytidylic (Poly I:C) rodent model of schizophrenia. Auditory
sensorimotor gating was assessed using prepulse inhibition and microglial activation was
examined and quantified using immunohistochemistry and confocal microscopy, respectively.
Both PD2024 and PD340 alleviated auditory sensorimotor gating deficits and reduced microglia
activation and thereby demonstrated the ability to treat both the behavioral and
neuroinflammatory aspects of the disorder. These results are significant and suggest that neural
TNFα is a potential pharmacological target for the treatment of schizophrenia.
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CHAPTER 1
INTRODUCTION

Schizophrenia (SCZ) is a chronic and debilitating neurobehavioral disorder that affects an
estimated 21 million people worldwide (World Health Organization 2018). SCZ negatively
affects cognition, emotion, and behavior. The age at onset of SCZ is classically observed in
adolescence or during the beginning of adulthood. The prevalence of SCZ and other related
psychotic disorders range between 0.25% and 0.64% in the United States (Kessler et al. 2005;
Wu et al. 2006; Desai et al. 2013; National Institute of Mental Health 2018). Medications and
other therapeutic expenses for the treatment of SCZ annually costs the U.S. an estimated $62
billion (Fleischhacker et al. 2014). Diagnosis is not based on laboratory testing, but instead arises
from clinical observation and self-reporting (Gejman et al. 2010). Currently, there is no cure for
treating the behavioral disorder. Therefore, it becomes increasingly important to investigate new
approaches in order to understand SCZ and the psychophysiology involved.

Schizophrenia: Symptoms, Psychophysiology, & Treatments
Schizophrenia is a severe mental disorder accompanied by three categories of symptoms:
positive, negative, and cognitive. Associated positive symptoms include delusions, hallucinations
(usually auditory), paranoia, unusual ways of thinking, and movement disorders. These
symptoms are deemed positive due to the psychotic behaviors present that are not observed in
normal individuals. Positive symptoms are “added” to common behavior. Negative symptoms
relate to changes in common behavior and emotion and include a flat affect, reduction in speech,
anhedonia, and difficulties in beginning and finishing activities. Negative symptoms are
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“removed” from common behavior. Cognitive symptoms relate to disturbances in memory and
thinking. These symptoms are comprised of a lack of concentration, impaired executive
functioning, and the loss of ability to apply information shortly after just learning it. There are
many associated risk factors for developing SCZ, but the reason for this development is not yet
fully understood. The main risk factors shown to contribute to SCZ development later in life
include early viral infection, brain lesions, prenatal and neonatal malnutrition, recreational drug
abuse, and influences that impact psychosocial functioning (National Institute of Mental Health
2018). SCZ and associated symptoms are hypothesized to stem from a variety of biochemical
factors including increased dopamine D2 receptor sensitivity, glutamate dysregulation, and
recently, neuroinflammation.

Dopamine D2 Receptor Supersensitivity
There are five dopamine receptors (D1, D2, D3, D4, D5) found throughout the CNS.
They are G-protein-coupled receptors (GPCRs) located within the nerve cell membrane that are
activated by dopamine binding. The central hallmark of SCZ continues to be hypersensitivity of
the dopamine D2 family of receptors (Howes et al. 2017). Support for this notion comes from
positive symptom alleviation when treated with drugs that block dopamine binding to D2
receptors (Kusumi et al. 2015). Dopamine is a catecholamine neurotransmitter involved in
reward, executive function, motor control, motivation, and arousal. Dopamine is synthesized
from its precursor molecule, L-DOPA, which can also be used to make norepinephrine and
epinephrine. Discovery of the D2 receptor came from analysis of where antipsychotic drugs bind
via radioligand labeling (Madras 2013). Dopamine receptor signaling dysfunction has also been
associated with many other psychiatric disorders. It has been hypothesized that dopamine D2
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receptor supersensitivity observed in those diagnosed serves as compensation for initial trauma,
which thereby increases dopamine neurotransmission, overstimulates the dopamine system, and
creates SCZ symptomatology (Seeman and Seeman 2014). It is worth note that cocaine and
amphetamine hijack the dopaminergic system to induce delusional paranoia that resembles some
of the positive symptoms of SCZ. Dopamine D2 receptor supersensitivity has been shown to lead
to delusions (Howes and Kapur 2009), hallucinations (Garrett and Silva 2003), and cognitive
deficits (Seeman and Seeman 2014). Neonatal treatment with quinpirole, a dopamine D2/D3
agonist, increases the sensitivity of the dopamine D2 receptor and is used as an animal model of
SCZ (Brown et al. 2012).
In SCZ, there is not a change in the number of dopamine D2 receptors, but rather
overactivity and increased signaling of dopamine. Treatment today relies on drugs that block
dopamine D2 receptors with some affinity, although newer atypical antipsychotics also focus on
signaling in the serotonergic, histaminergic, and noradrenergic neurotransmitter systems. The
quality of life for those diagnosed has significantly improved as a result of antipsychotic
treatment regimes, however complete normalization of behavior is rarely accomplished (Harvey
et al. 2012). Antipsychotics with better efficacy are still being developed today as a result of our
constantly increasing knowledge regarding the pathology of neurotransmission in SCZ.

Glutamate & NMDA Receptor Hypothesis of SCZ
Stone et al. (2007) proposed a differing hypothesis suggesting SCZ may arise from a
deficit in glutamatergic neurotransmission, particularly through dysfunction of the N-methyl-Daspartate (NMDA) receptor. Glutamate is the most abundant excitatory neurotransmitter in the
nervous system (Meldrum 2000) and is involved in learning and memory processes (McEntee
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and Crook 1993). Glutamate binds to different receptors, one of which is the NMDA receptor.
The NMDA receptor is a ligand-gated ion channel located on the membrane of nerve cells that is
activated upon glutamate binding. NMDA receptors are also important in memory and synaptic
plasticity (Li and Tsien 2009). Binding of glutamate to the NMDA receptor allows Ca2+ to enter
into the neuron. Excess intracellular Ca2+ ultimately damages neurons, suggesting a mechanism
for neurodegeneration (Harvey et al. 2012). Multiple studies (Krystal et al. 1994; Morgan and
Curran 2006; Javitt 2007) have implicated the role of NMDA receptor dysfunction in SCZ,
resulting from administration of non-competitive NMDA receptor antagonists (ketamine and its
analog, phencyclidine). Phencyclidine (PCP) and ketamine inhibit cell depolarization to induce
SCZ-like associated deficits (Johnson and Jones 1990). Long-term administration of PCP in rats
was shown to elicit negative symptoms (Egerton et al. 2008) by blocking the reuptake of
dopamine, serotonin, and norepinephrine (Harvey et al. 2012), whereas ketamine generated
cognitive deficits. Evidence for NMDA receptor dysfunction and glutamate hypofunction has
also been observed in post mortem brain tissue (Howes et al. 2015). In SCZ, glutamate receptor
localization has been shown to be abnormally regulated, which could be due to dysregulation of
glutamate receptor trafficking molecules (Funk et al. 2009). Functional changes to the NMDA
receptor also impact glutamatergic signaling, as a subunit (GRIN2A) of the NMDA receptor was
found to be associated with SCZ in genetic analyses (Ripke et al. 2014).
Evidence for NMDA receptor dysfunction and glutamate dysregulation has also been
observed in vivo, using Single-Photon Emission Computerized Tomography (SPECT) and
Proton Magnetic Resonance Spectrometry (1H-MRS). Using SPECT, Pilowsky et al. (2006)
showed unmedicated patients diagnosed with SCZ had left hippocampal NMDA receptor activity
deficiencies. Bustillo et al. (2014) found an elevated glutamine:glutamate ratio in the anterior
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cingulate cortex using 1H-MRS, with a strong correlation between increased
glutamine:glutamate ratio and psychosis. Untreated, but diagnosed individuals have been shown
to have increased glutamate levels in the caudate nucleus, a region of the brain responsible for
many motor processes (de la Fuente-Sandoval et al. 2011), thereby further strengthening the
NMDA receptor/glutamate hypothesis. It is also worth note that dopamine antagonizes the
glutamate system, thus reducing glutamate release. Dopamine and glutamate dysregulation must
both be considered when analyzing mechanisms behind the development of SCZ. Thus, it can be
hypothesized that dopamine supersensitivity and deficits in glutamate neurotransmission are both
major biochemical factors that contribute to the disorder.

History of Treatment & Discovery of Antipsychotics
Treatment for SCZ before the middle of the 20th century initiated by confining patients
indefinitely to psychiatric hospitals, commonly referred to as mental asylums (Luo 2015).
Therapeutic pharmacological medicine did not yet exist, which lead to unusual approaches.
Patients diagnosed with SCZ were subjected to a plethora of interventions no longer used today,
including barbiturate-induced sleep therapy, comas (from high insulin doses), and neurosurgeries
(Valenstein 1986). Barbiturate-induced sleep therapy was proposed to alleviate lethargy in those
diagnosed, thus improving patient psychosocial functioning. However, this therapeutic technique
only acutely improved symptomatology, as patients would revert back to their initial state once
the barbiturate’s effect was eliminated (López-Muñoz et al. 2005). Early studies suggested high
insulin doses could reduce psychotic episodes, but instead resulted in loss of consciousness and
seizures. Lobotomy of the frontal lobe was also suggested as a method to reduce agitation and
impulsive behavior, but was shown to lead to cognitive impairment with no reported benefits

14

(Lavretsky 2008). Psychoanalysis, an investigation into the subconscious factors that contribute
to mental illness, was used in both the U.S. and the United Kingdom, but proved ineffective
(Guttmacher 1964; Lavretsky 2008). As a result, the quality of life for those diagnosed did not
significantly improve and patients were without an effective treatment option.
The first antipsychotic drug, chlorpromazine, was discovered in 1952. Since the
discovery of chlorpromazine, approximately fifty antipsychotic drugs have been developed.
Chlorpromazine was created by the modification of promethazine, a drug used to treat
circulatory shock after surgery (Lavretsky 2008). Chlorpromazine was found to alleviate many
positive symptoms of SCZ, increase social functioning, and reduce relapse rates (Lavretsky
2008; Luo 2015). The discovery of chlorpromazine thus began the development of firstgeneration antipsychotics (FGAs). Common FGAs still prescribed today include
chlorprothixene, perphenazine, and haloperidol. FGAs are competitive dopamine D2 receptor
antagonists, but also modulate other neurotransmitters, as discussed with SGAs. FGA are termed
either as “low-potency” or “high-potency” to indicate their affinity for the D2 receptor. By
blocking the dopamine D2 receptor, FGAs reduce psychosis and delay symptom exacerbations
(Carpenter and Koenig 2008). However, FGA are generally not effective for treating negative
symptoms and generate many unwanted side effects. For example, reserpine was discovered
shortly after chlorpromazine and was already used to treat hypertension. Reserpine reduces
synaptic dopamine release (Carpenter and Koenig 2008) leading to a decrease in dopamine levels
within the brain. As a result of depleting dopamine, treatment with reserpine has been shown to
create Parkinson’s-like symptoms (Luo 2015), further confirming the existence of negative sideeffects that accompany FGA treatment. Second-generation antipsychotics (SGAs) were
developed to reduce common side effects generated by FGA treatment and to improve negative
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symptomatology. The first SGA, risperidone, was discovered in 1996. Other commonly known
SGAs include clozapine, olanzapine, ziprasidone, and quetiapine. SGAs block dopamine D2
receptors in the brain similar to FGAs, and also block cholinergic, adrenergic, serotonergic
(particularly 5-HT2A), and histaminergic receptors. Risperidone, in particular, blocks serotonin 5HT2A receptors with more affinity than dopamine D2 receptors. Quetiapine also blocks D2
receptors with a greater affinity than 5-HT2A receptors (López-Muñoz and Alamo 2013). Another
SGA with a different pharmacodynamic profile than risperidone and quetiapine is clozapine.
Clozapine is a weak dopamine D2 receptor antagonist, but has a high affinity for other key
receptors including 5-HT2, muscarinic, and -adrenergic receptors (Chaki et al. 2000). Clozapine
and other SGAs have been shown to some extent to ameliorate negative symptoms of SCZ,
although none have been shown to be completely effective. Besides serving as an antipsychotic
medication, the FDA also approved the use of clozapine as an anti-suicidal treatment option
(Meltzer 2005), thereby demonstrating the ability of the drug to be used in multiple capacities.
The problems with SGAs have also been due to side effects of these drugs, and their efficacy.
The Clinical Antipsychotic Trials for Intervention Effectiveness (CATIE) sponsored by the
National Institute of Mental Health revealed that compliance to SGAs was poor, and all were
below 20%. Compliance was low primarily due to side effects of these drugs, including most
prominently weight gain and extrapyramidal motor effects (Manschreck and Boshes 2007).
Therefore, it is clear that new pharmacological targets are greatly needed for treatment of this
population.
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Problems with Current Treatment
Even though antipsychotic medications remain as the first-line of treatment for SCZ and
SCZ-like disorders, many problems also result from current treatments. It is also of note that
approximately 20% of patients diagnosed with SCZ do not respond to antipsychotic treatment
(Harvey et al. 2012). There are many debilitating side effects that accompany an antipsychotic
treatment regime. These include extrapyramidal side effects (EPS), weight gain, and increased
risk of diabetes mellitus (DM) development, hyperlipidemia, and agranulocytosis. These side
effects have been observed in both typical and atypical antipsychotic treatment regimes, usually
on a dose-dependent basis. Henceforth, the focus will be on the accompanying side effects
observed in both typical (FGA) and atypical (SGA) antipsychotics, including specific side effects
reported more often with certain drugs.
A recent review by Divac et al. (2014) provided a thorough investigation into the EPS
that follows treatment with an antipsychotic. EPS are serious and incapacitating, often requiring
additional pharmacological intervention. EPS are developed as a result from the blocking of
dopamine receptors in the nigrostriatal pathway (Harvey et al. 2012). Acute EPS develop at
treatment initiation or when required dosage is increased to achieve therapeutic value. Prolonged
treatment with antipsychotics, particularly FGA, can also lead to late-onset EPS, including
tardive dyskinesia (involuntary somatic movement). EPS manifestations impair motor patterns
and include acute dystonia, akathisia, and Parkinsonism.
Acute EPS usually responds to a reduction in antipsychotic medication, often attracting
patients to discontinue treatment in order to alleviate the symptoms. Within the first few days of
antipsychotic treatment, approximately 50% of patients treated with haloperidol developed acute
EPS (Divac et al. 2014). Discontinuation of treatment also results from the risk for developing
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tardive dyskinesia (TD), which severely decreases quality of life and can even persist after the
abolishment of treatment (Casey 2004; Rosenheck 2007). The average prevalence of TD after
treatment has been shown to be between 24-30% (Casey 1999; Llorca et al. 2002). Clozapine, an
atypical antipsychotic, is the only known antipsychotic that does not cause acute EPS, but does
cause agranulocytosis, a life-threatening condition of severe leukopenia that if untreated, can
lead to septicemia. Clozapine can also suppress the bone marrow and increase the risk of seizures
and cardiovascular abnormalities (Harvey et al. 2012).
Acute dystonia is a neurological motor pattern disorder that results in repetitive muscle
contractions, which can lead to abnormally fixed postures. Acute dystonia is commonly seen in
first-generation antipsychotics (FGA). Although less common, dystonia can still be present in
second-generation antipsychotics (SGA). Kamishima et al. (2009) found approximately 7% of
patients that were treated with long-acting risperidone developed acute dystonia reactions.
Akathisia (approximately 50% of all cases of EPS) is a movement disorder characterized by the
inability to remain still due to feelings of inner restlessness. Akathisia is a common side effect
that follows treatment, but remains poorly understood. Approximately 25% of patients treated
with a FGA medication develop akathisia (Divac et al. 2014). Anticholinergic medication does
not affect akathisia, but dose-reduction of antipsychotics or introduction of beta adrenergic
blockers and benzodiazepines have proven to be effective (Shirzadi and Ghaemi 2006; Poznic et
al. 2012).
Parkinsonism is characterized by tremor, decreased body movement, and rigidity and
thereby mimics some of main symptoms seen in Parkinson’s disease. Parkinsonism develops
within the first few days up to several months after treatment starts. 26% of patients treated with
olanzapine and 55% treated with haloperidol develop Parkinsonism (Lieberman et al. 2003).
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Parkinsonism induced by antipsychotic medications is reversible via anticholinergics and dosereduction, although symptom duration varies. However, anticholinergics have to be closely
monitored when administered to elderly patients due to the accompanying cognitive decline,
urinary retention, and exacerbation of glaucoma that can result (Divac et al. 2014). Late-onset
EPS like TD can occur months to years after treatment begins. TD is characterized by
involuntary body movements that results from antipsychotic drug treatment. Shirzadi and
Ghaemi (2006) found the risk of developing TD to be the highest during the first five years
following FGA treatment. Anticholinergic intervention following antipsychotic administration
has also been shown to exacerbate existing TD (Divac et al. 2014).
Both FGA and SGA drugs have been found to contribute to weight gain and negative
metabolic side effects (Allison et al. 1999; Wirshing et al. 1999; Allison and Casey 2001).
Weight gain in particular is mediated by the antihistaminic action of FGA and SGA drugs. Short
or long-term administration of antipsychotics antagonizes histamine H1 receptors, affects
hypothalamus-brain stem circuitry, and ultimately increases appetite and fat accumulation (He et
al. 2013). For example, the common over-the-counter anti-allergy medication, Benadryl
(diphenhydramine), also antagonizes histamine receptors and if used long-term, can lead to
significant increases in body weight (Hasnain and Viewig 2013). SGA are associated with a
higher risk for developing these side effects (Harvey et al. 2012). Allison and Casey (2001)
showed mean body weight increases of 4.45 kg (clozapine), 4.15 kg (olanzapine), 2.92 kg
(sertindole), 2.10 kg (risperidone), and 0.04 kg (ziprasidone) following treatment. Nemeroff
(1997) also found the most commonly used dose of olanzapine (15 mg/day) lead to a 10-kg
weight increase during the first year of treatment, with weight gain being dose-dependent.
Rondanelli et al. (2006) highlighted the importance of dosage on side effects, showing elderly
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patients that received 1.4 mg/day of risperidone or 4.4 mg/day of olanzapine, or 75 mg/day of
quetiapine had no change in weight during a one year period.
Antipsychotic intervention may lead to an increased risk for the development of diabetes
mellitus (DM). Multiple studies have reported antipsychotic use to be strongly associated with
weight gain (e. g. olanzapine, clozapine) and also strongly increase the risk for developing DM
and diabetic ketoacidosis (Fuller et al. 2003; Guo et al. 2006; Haupt 2006; Rubio et al. 2006).
Multiple studies have also demonstrated increased cholesterol and serum triglyceride levels in
patients following treatment with dibenzodiazepine-derived SGA (e. g. clozapine, olanzapine,
quetiapine) over a two-month period (Meyer 2002; Wu et al. 2006).
As a result of many unwanted side effects, discontinuation of treatment with both FGA
and SGA is often reported. Again, the CATIE study was designed to examine many of the
factors involved in discontinuation of antipsychotic medications. Subjects that had received a
diagnosis of SCZ were randomly assigned to receive either olanzapine, perphenazine, quetiapine,
risperidone, or ziprasidone in a double-blind experimental approach. The subjects were
monitored for 18 months or until treatment discontinuation. The CATIE trials found that 74% of
participants discontinued their prescribed medication (olanzapine = 64%, perphenazine = 75%,
quetiapine = 82%, risperidone = 74%, ziprasidone = 77%) before the 18 months were completed
(Swartz et al. 2008). Factors leading to discontinuation included EPS, weight gain, and onset of
DM. Weight gain was strongly associated with olanzapine specifically, but was observed in
some extent for all medications.
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Neuroinflammatory Aspect of Schizophrenia
Inflammation is the initial response of the immune system that results from the host’s
defense mechanism to eliminate a foreign threat caused by infection or trauma (Chen et al.
2018). Leukocytes migrate to the area of interest and blood supply increases. Early pathogenic
infection during gestation has been shown to increase the risk for developing SCZ later in life
(Kneeland and Fatemi 2013). Inflammation that follows an early developmental infection
persists throughout the lifetime, often causing autoimmune diseases (Ercolini and Miller 2009)
and sometimes crosses the blood-brain barrier (BBB) to damage key components within the
brain. In turn, neuronal plasticity is disrupted and cytokines/neurotransmitters become
abnormally regulated. One hypothesis suggests that disruptions in the developing immune
system are driving influences behind psychotic episodes and brain changes (Cannon et al. 2003)
observed in SCZ, including enlarged ventricle size, reductions in gray matter and whole-brain
volume, and differences in white matter (Vita et al. 2012).
Inflammation is maintained by amplified cytokine production. Cytokines are small
glycoproteins involved in cell-to-cell communication between immune cells. Cytokines are
produced by many types of cells including, but not limited to, macrophages, lymphocytes, and
granulocytes. Cytokines, particularly pro-inflammatory cytokines, contribute to inflammation
and remain present until the threat has been neutralized. Pro-inflammatory cytokines are
produced primarily by activated macrophages and neurons in the brain to help up-regulate the
inflammatory response (Zhang and An 2009).
In those diagnosed with SCZ, there is an unusual and elevated peripheral recruitment
pattern (Schroeter et al. 2009) of immune cells, leading to the generation of inflammatory
cytokines, particularly tumor necrosis factor-alpha (TNFα) (Miller et al. 2011; McCusker and
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Kelley 2013). Post mortem brain studies further confirm this report by demonstrating TNFα
levels were significantly (30-50%) higher in the prefrontal cortex (PFC) and hippocampal (HPC)
regions of the SCZ brain compared to unaffected individuals (Kim and Webster 2009). TNFα is
released from leukocytes (white blood cells) during the acute phase reaction of inflammation and
regulates the coordination between immune cells via cellular signaling. Along with generating
inflammation, TNFα can induce fever and trigger apoptosis. Elevated TNFα protein levels have
already been implicated in autoimmune diseases such as rheumatoid arthritis, where current
treatment relies on TNFα inhibitors (e. g. Infliximab, Etanercept, Adalimumab) to reduce
inflammation through antagonism of the cytokine (Ma and Xu 2013). TNFα also directly
influences the state of microglial cells, which are the residence surveillance cells of the CNS
(Nimmerjahn et al. 2005).
Microglia are a type of glial cell found within the brain and spinal cord (Ginhoux et al.
2013) and account for between 5-20% of the total glia population within the CNS parenchyma
(Perry 1998). Without a stimulus (e. g. pro-inflammatory cytokine), microglial cells exist in a
“M2 state” that is anti-inflammatory and neuroprotective. These microglia in an M2 state help to
protect the brain from inflammation and promote neurogenesis and plasticity. When a stimulus,
such as increased TNFα protein secretion is present, M2 microglia switch to a “M1 state”, which
aids in the inflammatory response and becomes neurotoxic to help deal with the threat. Once
reactive, microglia cells via a positive feedback loop overexpress pro-inflammatory cytokines
and generate reactive oxygen species (ROS) that damages neuronal synapses and leads to
unnecessary neuronal apoptosis and necrosis (Howes and McCutcheon 2017). Recent work
(Perry et al. 2010; Kettenmann et al. 2011) suggests that dysregulated reactive microglial cells
can ultimately lead to disease and pathology development. Reactive microgliosis (increase in
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microglial cell number) has also been reported in many CNS diseases in response to elevated
inflammation (Ginhoux et al. 2013).
For those diagnosed with SCZ, neuroinflammation is characterized by M1 microglial cell
activation. Multiple studies (Steiner et al. 2008; Fillman et al. 2013; Volk 2017) have shown a
direct link between microglial activation and SCZ, particularly in brain regions where white
matter is present. As a result, it can be suggested that microglial activation is directly related to
certain SCZ symptoms. Recent work has demonstrated the effectiveness of anti-inflammatory
compounds as treatment options for SCZ. For example, minocycline, a broad-spectrum
tetracycline antibiotic that also has anti-inflammatory properties has been shown to significantly
reduce positive and negative symptom severity compared to placebo (Solmi et al. 2017; Xiang et
al. 2017). Studies also reported that minocycline alleviated prepulse inhibition deficits (Zhu et al.
2016; Giovanoli et al. 2016) in the Poly I:C rodent model of SCZ, which was used for this
current study. Minocycline is able to cross the BBB, suggesting potential downregulation of
reactive microglial cells, thus reducing neuroinflammation and improving the associated
symptomology of SCZ.

P2D Bioscience, Inc. Previous Studies: Focus on Alzheimer’s Disease
Neuroinflammation also continues to gain ground as one of the central factors in
Alzheimer’s disease (AD) pathology. Multiple studies in AD patients (Kwak et al. 2014; Lynch
2014) have demonstrated an elevated recruitment pattern of leukocytes into the brain and their
corresponding interactions with resident microglia. It is still unclear if this recruitment brings
about damage to the AD brain, but it can be suggested that this increased infiltration is not
usually present in unaffected individuals. One of the pro-inflammatory cytokines ultimately
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contributing to this recruitment and increased inflammation is tumor necrosis factor-alpha
(TNF), as recent work has shown (McAlpine and Tansey 2008) it to be significantly implicated
in the disease. Again, TNFα polarizes microglia into different neuroinflammatory types, often
activating them into their M1 state to become pro-inflammatory and neurotoxic. Therefore, our
collaborators (Gabbita et al. 2015) investigated the inhibition/modulation of leukocytes upon the
interaction with microglial cells through the use of a novel pro-inflammatory cytokine inhibitor,
isoindolin-1,3 dithione (IDT), also termed PD2024, to target neural TNF and determine what
effect(s) it had on AD pathology.
One of the drugs used in the present study is PD2024. PD2024 is a small anti-TNF
molecule with a molecular weight of 179.0 g/mol and an IC50 for TNF-alpha of 3 M. Gabbita et
al. (2015) reported PD2024 was effective for treating many aspects pertaining to AD. In the BV2
microglial cell line, TNF response from lipopolysaccharide (LPS) stimulation was attenuated
alongside of increasing doses of PD2024, thus demonstrating the effectiveness of PD2024 in
vitro. TNF attenuation was found to be due to the ability of PD2024 to destabilize TNF
mRNA, thereby decreasing TNF protein release and secretion.
Then the Gabbita et al. (2015) study investigated the effectiveness of PD2024 to
modulate TNF in vivo. Following an IP 5 mg/kg LPS challenge and oral PD2024 treatment,
cortical levels of TNFα protein was increased and significantly reduced alongside of increasing
concentrations of PD2024. PD2024 was found in the brain (brain coefficient = 0.25) at detectable
amounts moderately comparable to levels found in the tissues. These results thereby revealed
that PD2024 was orally bioavailable, crossed the blood-brain barrier, and is effective in reducing
TNF protein levels.
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Finally, Gabbita et al. (2015) examined the effects of PD2024 on normal body weight and
weight gain in the 3xTgAD mouse model of AD. The 3xTgAD model is triple-transgenic and
consists of three specific mutations (APP Swedish, MAPT P301L, PSEN1 M146V) used to
represent familial Alzheimer’s disease. These mutations generate amyloid-beta (A) plaques and
neurofibrillary tangles (NFT), which are central pathology observed in those affected. At low
doses (10 mg/kg), PD2024 did not affect weight gain in males or females. However, at both
medium (25 mg/kg) and high (50 mg/kg) doses, it was found that weight gain was significantly
reduced in both genders, but this did not have an effect on health, activity levels, or cognitive
abilities.
With direct relevance to AD, the authors reported a dose-dependent response of PD2024
treatment with improved cognitive performance on the Barnes Maze (used to test spatial
awareness and long-term memory) in 3xTgAD mice. PD2024 was also found to reduce insoluble
amyloid levels and paired-helical filament (PHF) tau, two of the four primary characteristics of
human AD. They hypothesized this could be because PD2024 treatment may allow
microglia/macrophages to gain an improved ability to alleviate some of the neuropathology
involved. PD2024 was also found to increase infiltrating neutrophils in a dose-dependent manner
while also reducing TNF protein in the central nervous system (CNS). This is of particular
importance in regard to neuroinflammation because increased TNFα protein levels negatively
regulate neutrophils by the suppression of p40, a subunit of interleukin-23 (IL-23). This study
found PD2024 upregulates p40 gene expression, thereby suggesting PD2024 decreases
neuroinflammation via mediation of increased neutrophil infiltration into the CNS.
The results of this study confirmed a small TNFα modulator such as PD2024 is safe and
well-tolerated, decreases neuroinflammation via TNF mRNA destabilization, allows neutrophil
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infiltration into the CNS to clear AD pathology, and improves cognitive performance. PD2024 is
also being developed to treat frontotemporal dementia. Since PD2024 was found to modulate
neural TNFα, our study aimed to investigate if this could alleviate the associated
neuroinflammation observed in a rodent model of SCZ.
A second novel TNFα modulator (PD340) will also be analyzed in this study. PD340
contains an isoindoline backbone and is a structural analog of PD2024. This compound has yet to
be tested in a rodent model of any disease. Although the structure of the compound cannot be
revealed due to proprietary information, the drug is designed to modulate TNFα in a similar
fashion to PD2024 and has a similar pharmacokinetic profile. We thereby expect PD2024 to
have a comparable efficacy for alleviating sensorimotor gating deficits and decreasing microglial
cell activation.

Poly I:C Rodent Model of Schizophrenia
All experiments conducted in this study use the polyinosinic:polycytidylic acid (Poly I:C)
rodent model of schizophrenia. Poly I:C is an immunostimulant that interacts with the rich,
positively-charged amino acid surface of the toll-like receptor 3 (TLR3) within the cell to
stimulate and activate the innate immune system and trigger the release of a large number of proinflammatory cytokines. The activation of pro-inflammatory cytokines by Poly I:C, particularly
TNFα, leads to increased microglial cell activation, known to facilitate white matter injury and
neuronal apoptosis (Leviton and Gressens 2007; Khwaja and Volpe 2008). Early challenges to
the immune system compromise its integrity, thereby disrupting the cytokine equilibrium in the
developing brain (Welberg et al. 2000; Seckl 2004; Mueller and Bale 2008). In doing so, Poly
I:C generates an infection phenotype that is restricted to a maximum period of 1-2 days through a
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surplus of endocrine, autonomic, and behavioral symptoms induced by this immune activation
(Cunningham et al. 2007). The corresponding cytokine imbalance disrupts the structural and
functional integrity of the developing brain, ultimately leading to long-lasting consequences later
in life (Zhao and Schwartz 1998; Patterson 2007; Meyer et al. 2009; Burd et al. 2012).
Past work (Gandhi et al. 2007; Ribeiro et al. 2013) demonstrated neonatal Poly I:C
administration in rats elevates pro-inflammatory cytokine levels and reactive microglial cells in
the hippocampus (HPC) and prefrontal cortex (PFC) in the brain. As a result, behavioral deficits
emerged including cognitive deficits, deficits in sensorimotor gating (Ozawa et al. 2006;
Osborne et al. 2017), and anhedonia (Khan et al. 2014; Missault 2014). Also, Poly I:C
administered maternally was shown to create dopamine hyperfunction and structural
abnormalities in cortical volumes of the HPC and PFC in offspring (Buschert et al. 2016;
Meehan et al. 2017). Maternal exposure during gestation (day 9 and 12.5) generated
sensorimotor gating deficits, decreased PPI, and increased startle sensitivity (Meyer et al. 2005;
Meyer et al. 2006). Therefore, both maternal and neonatal exposure to Poly I:C produce many
characteristic symptoms that are hallmarks of SCZ.
Antipsychotic treatment with clozapine (Ribeiro et al. 2013) and risperidone (Piontkewitz
et al. 2011) were shown to alleviate many of the behavioral deficits observed in rats that were
treated early with Poly I:C, increasing the validity of this model. Deficits in behavior related to
brain structure abnormalities have also been found to be reversible following pharmacological
treatment, thereby demonstrating predictive validity of the Poly I:C model. The Poly I:C model
allows for precise timing of immunogenic impact as well as the intensity of the associated
stimulation with defined stages of brain development (Rutledge 1997). This preclinical model
thereby represents the ability for the screening of new pharmacological compounds without
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regard to drug interactions to be analyzed in both adolescence and adulthood. This is of top
priority for the treatment of SCZ due to the onset of clinical symptoms appearing at these two
particular time periods.
Our study capitalizes on these principles through the use of neonatal (postnatal days 5-7)
Poly I:C treatment in rats to activate the innate immune response early, disrupt the cytokine
balance within the brain, generate reactive microglial cells, and result in behavioral deficits that
mimic the same behavioral deficits observed in individuals diagnosed with SCZ. In doing so, the
Poly I:C model is able to mimic an exposure to an early infection that disrupts
neurodevelopment, shown to increase the risk for developing SCZ and SCZ-like disorders later
in life (Meyer 2014; Flinkkilä 2016). Using this model, we are able to analyze new
pharmacological targets to alleviate associated behavioral and neuroinflammatory aspects of
SCZ.

Hypotheses & Rationale
This research seeks to determine the behavioral and neuroinflammatory effects of two
novel TNFα modulators produced by our collaborators at P2D Bioscience, Inc. (Cincinnati, OH)
in the polyinosinic:polycytidylic (Poly I:C) rodent model of schizophrenia. Using relevant
literature and recent work, the following hypotheses were tested: (1) Treatment with Poly I:C
will increase TNFα protein levels similar to the neuroinflammatory response for individuals
diagnosed with schizophrenia; (2) Novel TNFα modulators will alleviate sensorimotor gating
deficits of the rodent Poly I:C model; (3) Novel TNFα modulators will reduce associated
neuroinflammation via a decrease in microglial cell activation levels in the hippocampus and
prefrontal cortex, two brain areas that mediate sensorimotor gating.
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The effects of the two TNF-alpha modulators (PD2024 and PD340) will be assessed
through the use of prepulse inhibition and quantification of the prefrontal cortex and
hippocampus via immunohistochemistry and confocal microscopy. The results of this study will
analyze a novel pharmacological target for schizophrenia. This study will also provide
investigation into the neuroinflammatory role of the behavioral disorder through the use of a
well-validated rodent model of schizophrenia.
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CHAPTER 2
MATERIALS AND METHODS

Experimental Design
Experiment 1 tested the hypothesis that Poly I:C administration increases TNFα protein
levels in the brain. In this experiment, pups were intraperitoneally (IP) injected with either Poly
I:C (2 mg/kg) or saline (0.9% NaCl) from postnatal days (P) 5-7. Rats were sacrificed at P30 in
accordance with when dietary manipulation for the experiments to assess the TNFα modulators
was to initiate. The prefrontal cortex (PFC) and hippocampus (HPC) were dissected away and
TNFα protein concentration was analyzed using a TNF enzyme linked immunosorbent assay
(ELISA) kit from Biomatik, Inc. (Wilmington, DE).
Experiment 2 tested the hypothesis that novel TNFα modulator PD2024 would alleviate
deficits in sensorimotor gating of the rodent Poly I:C model. This was accomplished by equally
dividing pups into four groups, each with differing experimental conditions (Poly IC/Control,
Poly IC/PD2024, Saline/Control, Saline/PD2024). Pups in the Poly I:C groups (Poly IC/Control,
Poly IC/PD2024) were IP injected with Poly I:C (2 mg/kg) from P5-7, whereas pups in the two
saline groups (Saline/Control, Saline/PD2024) were IP injected with saline (1 mg/kg) from
postnatal days 5-7. All pups were weaned from the female dam at P21 and then subjected to
dietary manipulation beginning at P30. Those in the PD2024 groups (Poly IC/PD2024,
Saline/PD2024) received a diet containing bioavailable PD2024 and remained on this diet until
P67. Those in the control groups (Poly IC/Control, Saline/Control) received a normal diet until
P67, where all four groups were then sacrificed. Prepulse inhibition (PPI) was used to assess
auditory sensorimotor gating using behavioral software and equipment from Kinder Scientific,
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Inc. (Poway, CA). Animals from all groups were behaviorally tested on PPI in both adolescence
(postnatal days 44-46) and adulthood (postnatal days 60-67). PPI allowed for behavioral
assessment and comparison between the four groups to determine what effect(s) the modulator
had on auditory sensorimotor gating.
Experiment 3 tested the hypothesis that the novel TNFα modulator PD340 would
alleviate deficits in sensorimotor gating of the rodent Poly I:C model. Again, PD340 is a small
anti-TNF molecule that destabilizes TNF mRNA, thereby decreases TNF protein formation
and later secretion. PD340 contains an isoindoline backbone and is a structural analog of
PD2024. Further details regarding PD340 are limited due to proprietary information. Experiment
3 was used to determine basic efficacies of PD340 and if similarities to PD2024 existed. The
same procedures were followed as in Experiment 2, with the exception that PD340 was
presented in the diet during the adolescent period instead of PD2024.
In both Experiments 2 and 3, we analyzed whether novel TNFα modulators PD2024 and
PD340 would reduce the associated neuroinflammation created by Poly I:C administration via a
decrease in microglial activation levels. This was accomplished following the same procedures
described in the second aim of this study. Upon animal sacrifice at P67, the prefrontal cortex
(PFC) and hippocampal (HPC) regions of the brain were dissected away and analyzed via
immunohistochemistry (IHC) and confocal microscopy. IHC and confocal microscopy allowed
for assessment and comparison of neuroinflammatory levels via microglial cell activation to
compare the effects of PD2024 and PD340 across groups.
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Subjects
Male Sprague-Dawley rats that were the offspring of adult male and female breeders
ordered from Envigo, Inc. (Indianapolis, IN) served as subjects. Female rats were not used as
subjects because it has been equivocal as to whether Poly I:C treated females demonstrate PPI
deficits (Bitanihirwe et al. 2010; Zhang et al. 2011; Howland et al. 2012). All animals were
housed in a climate-controlled vivarium with a 12-hour light/dark cycle throughout the course of
this experiment and food and water was available ad libitum. Rats from each litter were
randomly assigned to each drug/diet condition. Day of birth was termed as P0. Regardless of
experimental condition, animals remained with their respective female dam from postnatal day
(P)1-21 and were then socially housed from P22-30. In Experiments 2 and 3, at P30, dietary
manipulation began and animals were socially housed until P67, where they were then sacrificed
and brain tissue analyses began.

Experiment 1: TNFα Protein ELISA
A total of 17 Sprague-Dawley rats were IP administered saline (1 mg/kg – N=8) or Poly
I:C (2 mg/kg – N=9) from postnatal days 5-7 and raised until P30. At P30, brain tissue was
harvested and the prefrontal cortex (PFC) and hippocampus (HPC) were dissected away and
frozen on dry ice. Brain tissue from these animals were analyzed using a TNFα enzyme-linked
immunosorbent assay (ELISA) kit (Biomatik, Wilmington, DE) to verify administration of Poly
I:C increased TNFα protein levels in the PFC and HPC.

32

ELISA Procedure
We utilized a kit from Biomatik, Inc. (Wilmington, DE) to analyze TNFα protein levels.
A total of 500 μL of RIPA cell lysis buffer (150 mM NaCl, 50 mM Tris-HCl, 1.0% NP-40, 0.5%
sodium deoxycholate and 0.1% sodium dodecyl sulfate) plus protease and phosphatase inhibitors
(P5726, P8340, P0044, Sigma-Aldrich, St. Louis, MO) was added to each sample and
homogenized using a Fisher Scientific sonic dismembrator 500 (Fisher Scientific, Inc., Atlanta,
GA). Homogenates were centrifuged at 10,000g for 5 minutes at 4 °C. The 96-well ELISA plate
was pre-coated with anti-TNFα polyclonal antibody (pAb) for each well. The standard curve was
prepared using the TNFα standard (10,000 pg/mL) supplied from the manufacturer. The standard
was diluted from the supplied diluent provided in the kit to reach a concentration range between
15.6-1,000 pg/mL. Tissue samples were also further diluted (1:50) before the assay. The plate
containing the standards and samples were incubated for 1 hour at room temperature. The
monoclonal antibody (mAb) was then added to each well, incubated for 1 hour at room
temperature, and was then followed by incubation with the conjugate antibody for one hour.
Fluorescent visualization was accomplished via the addition of 3,3',5,5'-Tetramethylbenzidine
(TMB) substrate to each well for an incubation period of 20 minutes at room temperature, and
was then stopped using 2N sulfuric acid. The plate(s) were read immediately following the
addition of the stop solution. Optical density was measured using a Bio- Tek ELx 800 microplate
reader (Winooski, VT) at a 450-nm wavelength.
Tumor necrosis factor-alpha (TNFα) protein levels were assessed using two TNFα
ELISA plates, one for the PFC and the other for the HPC. TNFα levels were analyzed using an
independent t-test to compare the effects of drug treatments on TNFα in each brain area. An
independent t-test was used to compare the means of the PFC and HPC and was used to
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determine significant differences between TNFα protein levels (dependent variable) by drug
manipulation (saline or Poly I:C – independent variable).

Experiments 2 & 3: Poly I:C Administration & Dietary Manipulation
In each of Experiments 2 and 3, animals were equally divided into groups. In Experiment
2, those conditions were: Poly IC/Control, Poly IC/PD2024, Saline/Control, Saline/PD2024. In
Experiment 3, those conditions were: Poly IC/Control, Poly IC/PD340, Saline/Control,
Saline/PD340. In both experiments, rats were intraperitoneally (IP) administered saline (1
mg/kg) or polyinosinic:polycytidylic acid (Poly I:C – 2 mg/kg) from P5-7. This particular period
of Poly I:C treatment has been shown to result in auditory sensorimotor gating deficits and in
microglial activation in the hippocampus (Ribeiro et al. 2013). At P30, rats were given a normal
diet or a diet containing one of the TNFα modulators (Dyets, Inc., Bethlehem PA). For
Experiment 2, PD2024 was given in a 10 mg/kg dose, based on past findings (Gabbita et al.
2015) that this dose was effective in a rodent model of Alzheimer’s disease. In Experiment 3,
PD340 was given at either low (10 mg/kg) or high (30 mg/kg) dose, because it has not been
determined which is the more effective dose for this novel drug. The chosen diet (normal or
experimental) remained until P67, where the animals were then sacrificed and brain tissue was
analyzed.

Experiments 2 & 3: Body Weight & Weight Gain
Animal weights from the four groups (Saline/Control, Poly IC/Control, Saline/PD2024,
Poly IC/PD2024) throughout 10-day time intervals (P30, P40, P50, P60) investigating PD2024
are presented in Table 1. Animal weights from the four groups (Saline/Control, Poly IC/Control,
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Saline/PD340, Poly IC/PD340) using the same time intervals (P30, P40, P50, P60) as PD2024
are presented in Table 2, which investigated PD340. Average weight and standard errors of the
mean are reported. A two-way analysis of variance (ANOVA) was used to determine if there
were significant interactions or differences in weights between the groups. The Newman-Keuls
post hoc test (p=0.05) was used to analyze significant interactions (p=0.05).

Experiments 2 & 3: Prepulse Inhibition (PPI) Procedure
All animals in Experiments 2 and 3 were tested once daily on auditory sensorimotor
gating task as measured through prepulse inhibition (PPI) at two distinct time periods, in
adolescence (P44-46) and adulthood (P60-66). Each daily session began with a 5-minute
habituation period with only the background noise (70 dB) present. After this habituation was
complete, animals were subjected to three different, randomly assigned trial types, which
included pulse, prepulse, and no stimulus trials. The pulse trial was a 120 decibel (dB) startle
pulse administered by itself. The prepulse trial was an auditory stimulus that was either 3, 6, or
12 dB above the 70-dB background noise. The no stimulus trial was when a stimulus was not
provided. A total of 5 pulse, 5 no stimulus, and 15 prepulse trials (5 trials of each 73, 76, and 82
dB) were presented in each training session. Rats were placed in a stainless-steel dome (height =
8 cm) that was attached to a platform (11 cm wide x 15 cm long) mounted on a stainless-steel
ellipse in a sound attenuating chamber (28 cm high x 30 cm wide x 36 cm depth). Animal
response was recorded and measured (in Newtons) within a 250-millisecond window
immediately following stimulus presentation through a computer interface. PPI also has direct
translational value for humans and is used today. Electrodes are placed on the orbicularis oculi
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and measures acoustic startle response via electrical skin conductivity in humans to measure the
startle responses (Takahashi et al. 2011).

PPI Statistical Analysis
A three-way repeated measures ANOVA was used to analyze PPI performance, with the
between subject factors neonatal drug treatment (Poly IC/Saline) and diet (Experiment 2:
PD2024/Control; Experiment 3: PD340 low dose, high dose, and control) and decibel level (73,
76, 82 dB) was the repeated measures factor. Days of testing were averaged together in
adolescence (P44-46) and in adulthood (P60-66) as one mean for each subject. The NewmanKeuls was used as the post hoc test to analyze any statistically significant interactions (p=0.05).

Immunohistochemistry (IHC) & Confocal Microscopy
Immunohistochemistry (IHC) was conducted on brain tissue collected from animals
tested in Experiments 2 and 3. On P67-69, these animals were anesthetized and intracardially
perfused with 4% paraformaldehyde (PFA). Brains were removed and stored in 20% sucrose for
48 hours and then transferred to a clean vial and stored at -80 °C. Tissue was coronally sectioned
at 50 μm thickness using a Leica cryostat. The prefrontal cortex (PFC) and hippocampus (HPC)
were sectioned and stored as free-floating sections in 0.1 M phosphate buffered saline (PBS) (pH
7.3) until IHC began.
Free-floating sections were washed four times in 0.1 M PBS (pH 7.3; 10 minutes each
wash). Sections were permeablized with 0.4% Triton X-100 in PBS containing 0.5% bovine
serum albumin (BSA) for 20 minutes. Sections were then blocked for 2 hours in PBS containing
10% normal donkey serum (Jackson ImmunoResearch Laboratories, West Grove, PA), 1% BSA,
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and 0.4% Triton X-100. Tissue sections were then incubated overnight at 4 °C in PBS, 1% BSA,
and 0.4% Triton X-100 with the primary antibody, Iba1 (1:1,000, catalog #019-19741) (Wako
Chemicals USA, Richmond, VA), which was used to label microglial cells. The next day,
sections were washed four times with 0.1 M PBS (pH 7.3; 10 minutes each). Sections were then
incubated for twenty minutes in PBS containing 0.4% Triton X-100 and 0.5% BSA. The
secondary antibody (1:200 dilution) used to emit fluorescence (AlexaFlour488 conjugated AntiRabbit IgG – Jackson ImmunoResearch Laboratories, West Grove, PA) was then added and
sections were incubated for 2 hours in PBS with 1% BSA and 0.4% Triton X-100. Sections were
then washed four times in 0.1 M PBS (pH 7.3; 10 minutes each) and then transferred to charged
slides. A drop of Citiflour mounting medium (Ted Pella, Inc., Redding, CA) was added to the
center of the tissue and coverglass was applied. The coverglass was sealed with clear nail polish
the following day and remained protected from light exposure until confocal microscopy
analysis.
Slides were examined at a magnification of 40x using a Leica TCS SP8 inverted confocal
microscope. Specifications (Smart Gain = 509.5 V, Smart Offset = -0.11%, Zoom = 2.0,
Objective Lens = 20x/0.75 Dry, Resolution = 1024 x 1024) remained constant throughout all
imaging. A 30.1 μm thickness was captured per image, and eight images were captured (4 PFC,
4 HPC images) per animal. Images were saved in TIFF format to be quantified using the
National Institutes of Health (NIH) ImageJ software. The NIH ImageJ software was bundled
with Java 1.8.0_172 for Mac OS X, https://imagej.nih.gov/ij/ to obtain statistical analysis and
evaluate overall image fluorescence (Figure 4). The rectangular box tool from ImageJ was used
to select the entire TIFF image. Integrated Density from ImageJ was used to obtain quantitative
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values for overall image fluorescence determination. Each TIFF image generated one data point
thereby giving eight representative data points combined from the two brain regions.

P5-7
Administer (IP) Poly I:C or Saline to Subjects

P30
Administer (Oral) PD2024, PD340, or Control Diet until P60

P40-44
Measure PPI Performance in Adolescence

P60-66
Measure PPI Performance in Early Adulthood

P67
Sacrifice, Perfuse, & Remove Brains

P68-71
IHC & Confocal Microscopy
Figure 1: Experiments 2 & 3 Flowchart. Flowchart outlining schedule and associated testing
procedures for these experiments.

Microglia Cell Count Analysis
Activated microglial cell counts were determined by two outside observers blind to the
study. The two participants each counted the total amount of fluorescently activated microglial
cells per image and the average number between the two observers was recorded. There was not
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significant variance in cell counts between the two observers. Each TIFF image generated one
data point, and eight TIFF images (4 PFC, 4 HPC) were taken, thus generating eight data points
per animal. Cell counts were analyzed with a one-way analysis of variance (ANOVA). The oneway ANOVA was selected to analyze each brain area and determine significant differences
between the variance of cell counts (dependent variable) by drug/treatment manipulation
(independent variable). The Newman-Keuls post hoc test (p=0.05) was used to analyze
significant interactions (p=0.05).

Microglial Cell Body Fluorescence Analysis
In addition to cell counts, we also sampled cell body fluorescence statistics from the
Integrated Density tool. These quantifications were analyzed with a one-way analysis of variance
(ANOVA). The one-way ANOVA was selected to analyze each brain area and determine
significant differences between the variance of sampled cell body fluorescence (dependent
variable) by drug/treatment manipulation (independent variable). The Newman-Keuls post hoc
test (p=0.05) was used to analyze significant interactions (p=0.05).
Finally, we also sampled overall image fluorescence statistics from the Integrated Density
tool, which was analyzed with a one-way analysis of variance (ANOVA). The one-way ANOVA
was selected to analyze each brain region and determine significant differences between the
variance of overall image fluorescence (dependent variable) by drug/treatment manipulation
(independent variable). The Newman-Keuls post hoc test (p=0.05) was used to analyze
significant interactions (p=0.05).
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CHAPTER 3
RESULTS

Experiment 1: TNFα ELISA Protein Levels
TNFα protein levels (pg/mg) are presented as a function of drug treatment group in
Figure 2. An independent t-test was used to analyze each brain area. For the HPC, the
independent t-test revealed a significant main effect of neonatal drug treatment in the dorsal
hippocampus t(12) = 2.21, p<0.5 as well as the ventral hippocampus t(12) = 3.16, p<0.01 with
Poly I:C treatment producing increases in both regions. Though elevated in the frontal cortex,
there was not a significant difference in TNFα levels due to high variability in the Poly I:C
treated group (N=5). Therefore, it appears that TNFα protein levels were significantly increased
by neonatal Poly I:C treatment in the hippocampal brain region.

Figure 2: TNFα Protein Levels Following Saline or Poly I:C Administration between P5-7.
Mean TNFα protein levels (pg/mg) in both the dorsal and ventral hippocampus and frontal
cortex following treatment with either saline (0.9% NaCl – N=8) or Poly I:C (2 mg/kg – N=9)
from postnatal days 5-7. Data represents the results of Experiment 1 (mean ± SEM). Data were
analyzed by an independent t-test (p<0.05).
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Experiment 2: PD2024 - Body Weights
Animal body weights following treatment with either neonatal saline or Poly I:C
treatment and with either PD2024 or control diet present were assessed from P30-60 (Table 1).
We analyzed the data in 10-day time intervals (P30, P40, P50, P60) to determine if significant
differences between neonatal or dietary manipulation groups were present. A two-way ANOVA
(neonatal drug treatment x diet) showed no significant main effects or interactions. Therefore,
dietary manipulation and/or drug treatment had no significant effect nor did they interact on
normal body weight or weight gain over the adolescent period.
Table 1: Animal Body Weights Across Experiment 2 Groups from P30-60. Mean body weight
(in grams) across neonatal drug treatments and diets from postnatal days 30-60 measured at 10day time intervals (Saline/Control N=5, Poly IC/Control N=6, Saline/PD2024 N=5, Poly
IC/PD2024 N=6) (mean ± SEM). Data were analyzed by a two-way ANOVA.
Neonatal Drug

Diet

Treatment

P30 Weight

P40 Weight

P50 Weight

P60 Weight

(g)

(g)

(g)

(g)

Saline

Control

87.7 ± 6.30

159.0 ± 7.67

223.4 ± 5.21

278.3 ± 7.2

Poly IC

Control

98.9 ± 2.29

170.3 ± 4.1

244.0 ± 4.25

304.1 ± 5.7

Saline

PD2024

100.3 ± 4.6

165.7 ± 5.6

226.0 ± 5.1

278.3 ± 7.1

Poly IC

PD2024

100.3 ± 2.65

168.4 ± 6.14

240.0 ± 9.8

294.4 ± 12.8

Experiment 2: PD2024 - Prepulse Inhibition Performance
Auditory sensorimotor gating measured by prepulse inhibition (PPI) performance is
presented in Figure 3A for adolescent rats and 3B for adults. PPI is presented as a function of
neonatal drug treatment and dietary condition. In adolescents (Figure 3A), a three-way ANOVA
revealed a significant two-way interaction of neonatal drug treatment x diet F(1,32) = 16.72,
p<0.001. At all prepulse intensities, Saline/Control and Poly IC/PD2024 groups were equivalent,
and showed significantly improved PPI performance compared to the Poly IC/Control and
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Saline/PD2024 groups. Furthermore, the Saline/Control group and Poly IC/PD2024 groups were
statistically equivalent across all prepulse decibel levels.
In adulthood (Figure 3B), a three-way ANOVA showed a significant main effect of diet
F(1,32) = 6.24, p<0.01 and a significant interaction of neonatal drug treatment x diet F(1,32) =
24.81, p<0.001. PPI deficits were found to be alleviated by PD2024 that was produced by
neonatal Poly I:C treatment and Poly IC/PD2024 was equivalent to Saline/PD2024 and
Saline/Controls. Poly I:C/Control animals demonstrated deficits at all three decibel levels.
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Figure 3: PPI Performance in Adolescents and Adults Across Experiment 2 Groups. Mean
PPI percentages across all prepulse trails (73 dB, 76 dB, and 82 dB) in both adolescence (P4446) and early adulthood (P60-66) following treatment with Poly I:C or saline and with either
PD2024 or control diet present (Saline/Control N=5, Poly IC/Control N=6, Saline/PD2024
N=5, Poly IC/PD2024 N=6) (mean ± SEM). Data were analyzed by a three-way ANOVA
(p<0.05).
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Experiment 2: PD2024 - Immunohistochemistry
There were no significant effects in microglial activation cell counts and overall
fluorescence. However, there were significant group differences on the microglial cell body
analysis. Microglial cell body activation is presented in the prefrontal cortex (PFC), CA1 and
CA3 regions of the hippocampus (HPC) as a function of neonatal drug treatment and dietary
condition in Figure 4. A one-way ANOVA revealed a significant main effect of group in the
PFC: F(3,15) = 8.0, p<0.003, HPC CA1: F(3,16) = 8.1, p<0.003, and HPC CA3: F(3,16) = 12.8,
p<0.001. Animals neonatally administered Poly I:C demonstrated a significant increase in
fluorescence intensity in microglial cells regardless of brain region. PD2024 reduced microglia
activation to control levels, suggesting PD2024 is effective in decreasing microglial cell
activation in Iba1 positive cells.
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Figure 4: Microglial Cell Activation in the PFC and HPC Across Experiment 2 Groups.
Microglial cell activation as measured by fluorescence intensity in the prefrontal cortex (PFC)
and CA1/CA3 regions of the hippocampus (HPC) following neonatal drug treatment (Saline or
Poly I:C) and/or dietary manipulation (PD2024 or Control) (Saline/Control N=5, Poly
IC/Control N=6, Saline/PD2024 N=5, Poly IC/PD2024 N=6) (mean ± SEM). Data were
assessed by a separate one-way ANOVA used to analyze each brain area.
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Poly IC/Control

Poly IC/PD2024

Saline/Control

Saline/PD2024

Figure 5: Representative Images of Flourescently Labeled Microglia Cells Across Experiment
2 Groups in the Prefrontal Cortex. One representative image from each group (Poly
IC/Control, Poly IC/PD2024, Saline/Control, Saline/PD2024) for GFP-labeled microglia cells
in the PFC (Scale bars, 100 μm).
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Poly IC/Control

Poly IC/PD2024

Saline/Control

Saline/PD2024

Figure 6: Representative Images of Flourescently Labeled Microglial Cells Across Experiment
2 Groups in the Hippocampus. One representative image from each group (Poly IC/Control,
Poly IC/2024, Saline/Control, Saline/PD2024) for GFP-microglia cells in the HPC (Scale bars,
100μm).
Experiment 3: PD340 - Body Weights
Animal body weight and weight gain following neonatal treatment with either saline or
Poly I:C and with either PD340 (10 mg/kg or 30 mg/kg) or control diet were assessed from P3060 and presented in Table 2. A two-way ANOVA revealed a significant main effect of group
F(5,36) = 3.4, p<0.01 and a significant group x day interaction F(15,108) = 8.41, p<0.001. A
Newman-Keuls post hoc test revealed all five groups were equivalent from P30-50, but several
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group differences emerged at P60. The Saline/Control and Poly IC/Control groups were
equivalent and had significantly greater body weights than all other groups. These results thereby
indicate PD340 decreases weight gain in neonatal saline and Poly I:C treated animals. Future
work could investigate PD340’s ability to be used as an adjunctive with an antipsychotic to
ameliorate weight gain that accompanies currently associated pharmacological treatment.
Table 2: Animal Body Weights Across Experiment 3 Groups from P30-60. Mean body weight
(in grams) across neonatal drug treatments and diets from postnatal days 30-60 measured at 10day time intervals (Saline/Control N=5, Poly IC/Control N=6, Saline/PD340 – 10 mg/kg N=5,
Saline/PD340 – 30 mg/kg N=5, Poly IC/PD340 – 10 mg/kg N=5, Poly IC/PD340 – 30 mg/kg
N=5) (mean  SEM). Data were analyzed by a two-way ANOVA (* indicates p<0.05).
Neonatal Drug

Diet

Treatment

P30 Weight

P40 Weight

P50 Weight

P60 Weight

(g)

(g)

(g)

(g)

Saline

Control

96.3  4.05

179.7  5.25

223.4  3.6

320.3  5.9*

Poly IC

Control

97.0  1.97

175.5  4.1

247.6  4.5

303.3  5.1*

Saline

PD340

98.12  3.9

175  4.0

244.4  4.5

294  5.2

93.1  3.0

159.1  5.4

223.8  5.5

267.6  5.1

96.87  3.9

172  6.1

238.88  5.4

287.75  6.4

95.38  4.4

161.1  5.3

227.4  7.4

273.5  7.0

10 mg/kg
Saline

PD340
30 mg/kg

Poly IC

PD340
10 mg/kg

Poly IC

PD340
30 mg/kg

Experiment 3: PD340 - Prepulse Inhibition Performance
Auditory sensorimotor gating as measured by prepulse inhibition (PPI) performance in
both adolescence and adulthood is presented in Figure 7. PPI is presented as a function of
neonatal drug treatment and dietary condition. In adolescents, a three-way ANOVA revealed a
significant main effect of diet F(2,41) = 3.90, p<0.02 and a significant two-way interaction of
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neonatal drug treatment x diet F(2,41) = 4.48, p<0.01. A Newman-Keuls post hoc test revealed
that the Poly IC/Control group was significantly lower than both PD340 treated groups as well as
the Saline/Control group at 73 and 82 dB. The PD340 (30 mg/kg) group was equivalent to the
Poly IC/Control group at 76 dB.
In adulthood, a three-way ANOVA revealed a significant main effect of diet F(2,41) =
4.73, p<0.01 and a significant interaction of neonatal drug treatment x diet F(2,41) = 5.38,
p<0.008. A Newman-Keuls post hoc test revealed that the Poly IC/Control group was
significantly lower than both PD340 treated groups and the Saline/Control group at all three
prepulse (73, 76, and 82) decibel levels. Regardless of dose, these results demonstrate PD340
alleviated sensorimotor gating deficits generated by neonatal Poly I:C treatment in adults.
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Figure 7: PPI Performance for Adolescents and Adults Across Experiment 3 Groups. Mean
PPI percentages across all prepulse trials (73 dB, 76 dB, and 82 dB) in both adolescence (P4446) and early adulthood (P60-66) following treatment with Poly I:C or saline and with either
PD340 (10 mg/kg or 30 mg/kg) or control diet present (Saline/Control N=5, Poly IC/Control
N=6, Saline/PD340 – 10 mg/kg N=5, Saline/PD340 – 30 mg/kg N=5, Poly IC/PD340 – 10
mg/kg N=5, Poly IC/PD340 – 30 mg/kg N=5) (mean ± SEM). Data were analyzed by a threeway ANOVA (p<0.05).
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Experiment 3: PD340 - Immunohistochemistry
There were significant group differences in microglial cell activation in all analyses,
including cell count, sampled cell body fluorescence, and overall image fluorescence. Cell
counts are presented as a function of the number of Iba1 positive cells as a function of brain area
and group in Figure 8. A two-way ANOVA revealed a significant main effect of diet in the PFC
F(2,42) = 6.63, p<0.01, but there were no significant main effects or interactions in the CA1 or
CA3 regions of the hippocampus. In the PFC, there was an overall increase in Iba1 positive cells
produced by PD340 in comparison to control diet. PD340 increased the number of Iba1 positive
cells regardless of dose.

Figure 8: Iba1 Positive Cell Counts in the PFC and HPC Across Experiment 3 Groups.
Microglial cell counts in the prefrontal cortex (PFC) and CA1/CA3 regions of the hippocampus
(HPC) following neonatal drug treatment (Saline or Poly I:C) and/or dietary manipulation
(PD340 – 10 mg/kg or 30 mg/kg) (Saline/Control N=5, Poly IC/Control N=6, Saline/PD340 –
10 mg/kg N=5, Saline/PD340 – 30 mg/kg N=5, Poly IC/PD340 – 10 mg/kg N=5, Poly IC/PD340
– 30 mg/kg N=5) (mean  SEM). Data were assessed by a two-way ANOVA used to analyze the
number of Iba1 positive cells as a function of brain area and group.
Cell body fluorescence is presented as a function of brain area and groups in Figure 9. A
two-way ANOVA for cell body fluorescence revealed significant main effects of diet in both
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CA1 F(1,41) = 5.47, p<0.02 and CA3 F(1,41) = 6.77, p<0.01, and significant interactions of
neonatal drug treatment x diet in both CA1 F(2,41) = 10.03, p<0.001 as well as CA3 F(2,41) =
15.44, p<0.001. In both hippocampal areas, CA1 and CA3, Poly IC/Controls demonstrated
higher amounts of cell body fluorescence intensity than all other groups. In the PFC, there was a
significant main effect of diet F(2,41) = 8.97, p<0.001. Surprisingly, PD340 produced an
increase in fluorescence intensity regardless of neonatal drug treatment as compared to saline
controls, but similar to cell counts in the PFC, these groups were not different from Poly
IC/Controls, and Poly IC/Controls were significantly greater than Saline/Controls.

Figure 9: Microglial Cell Activation in the PFC and HPC Across Experiment 3 Groups.
Microglial cell activation as measured by sampled cell body fluorescence intensity in the
prefrontal cortex (PFC) and CA1/CA3 regions of the hippocampus (HPC) following neonatal
drug treatment (Saline or Poly I:C) and/or dietary manipulation (PD340 – 10 mg/kg or 30
mg/kg) (Saline/Control N=5, Poly IC/Control N=6, Saline/PD340 – 10 mg/kg N=5,
Saline/PD340 – 30 mg/kg N=5, Poly IC/PD340 – 10 mg/kg N=5, Poly IC/PD340 – 30 mg/kg
N=5) (mean  SEM). Data were examined by a two-way ANOVA used to analyze the effects of
neonatal drug treatment and diet.
Overall image fluorescence is presented as a function of brain area and groups in Figure
10. A two-way ANOVA for overall image fluorescence revealed a significant main effect of diet
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for the PFC F(2,41) = 18.0, p<0.001, but no other significant main effects or interactions in the
CA1 or CA3 brain regions. Supporting our findings in the PFC in cell body fluorescence, PD340
produces an increase in microglial activation in this region regardless of neonatal drug treatment
as compared to controls, however in this case, there were no significant differences between Poly
IC/Controls and Saline/Controls in any brain region.

Figure 10: Overall Image Fluorescence Across Experiment 3 Groups in the PFC and HPC.
Overall image activation as measured by fluorescence intensity in the prefrontal cortex (PFC)
and CA1/CA3 regions of the hippocampus (HPC) following neonatal drug treatment (Saline or
Poly I:C) and/or dietary manipulation (PD340 – 10 mg/kg or 30 mg/kg) (Saline/Control N=5,
Poly IC/Control N=6, Saline/PD340 – 10 mg/kg N=5, Saline/PD340 – 30 mg/kg N=5, Poly
IC/PD340 – 10 mg/kg N=5, Poly IC/PD340 – 30 mg/kg N=5) (mean  SEM). Data were
assessed using a two-way ANOVA, which was used to analyze the effects of group and brain
area.
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Poly IC/PD340
10 mg/kg

Saline/PD340
10 mg/kg

Saline/PD340
30 mg/kg

Poly IC/PD340
30 mg/kg

Poly IC/Control

Saline/Control

Figure 11: Representative Images of Iba1 Labeled Microglia Cells Across Experiment 3
Groups in the Prefrontal Cortex. One image from each group (Poly IC/Control, Saline/Control,
Poly IC/PD340 – 10 mg/kg, Poly IC/PD340 – 30 mg/kg, Saline/PD340 – 10 mg/kg,
Saline/PD340 – 30 mg/kg) used to represent cell body fluorescence intensity in the PFC (Scale
bars, 100 μm).
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Poly IC/Control

Saline/PD340
10 mg/kg

Saline/PD340
30 mg/kg

Poly IC/PD340
10 mg/kg

Poly IC/PD340
30 mg/kg

Saline/Control

Figure 12: Representative Images of Iba1 Labeled Microglia Cells Across Experiment 3
Groups in the Hippocampus. One image from each group (Poly IC/Control, Saline/Control,
Poly IC/PD340 – 10 mg/kg, Poly IC/PD340 – 30 mg/kg, Saline/PD340 – 10 mg/kg,
Saline/PD340 – 30 mg/kg) used to represent cell body fluorescence intensity in the HPC (Scale
bars, 100 μm).
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CHAPTER 4
DISCUSSION

In this study, we were able to show neonatally administered Poly I:C increases
neuroinflammation within the brain and generates behavioral abnormalities in adolescence and
early adulthood, thereby validating the use of the Poly I:C model to mimic SCZ. Poly I:C was
also shown to generate reactive microglia in the PFC and HPC, two areas shown to be affected in
those diagnosed. When a novel TNF modulator was administered through the diet from early
adolescence to adulthood, sensorimotor gating deficits were alleviated and microglial cell
activation decreased, although not across all brain regions examined. Our two novel TNF
modulators did not increase weight gain, with one of the modulators, PD340, actually
significantly reducing weight gain when compared to the neonatal Poly I:C animals. This is an
important effect, because weight gain is a common side effects of antipsychotics. Both
modulators used in this study were proven to be safe and well-tolerated in all subjects, thereby
further demonstrating excellent preclinical data for the continued development of novel antiinflammatory drugs to be investigated as treatment for SCZ.

Poly I:C Administration Leads to Increased TNF-Alpha Protein Levels in the Brain
In Experiment 1, the analysis of TNFα protein revealed that neonatal Poly I:C
administration significantly increased levels of the pro-inflammatory cytokine, TNFα, compared
to controls in the two subregions of the hippocampus proper, CA1 and CA3. The hippocampus is
a brain area that is critically important in prepulse inhibition, as past work has demonstrated
deficits are present in those diagnosed with SCZ (Braff et al. 1978; Caine et al. 1992; Swerdlow
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et al. 2008) and the hippocampus is also critical in PPI in rats (Zhang et al. 2002). In addition,
the hippocampus plays a critical role in cognition as well as in behaviors related to the negative
symptoms often observed in schizophrenia (Howes et al. 2015).
There was a large variation in TNFα protein levels across animals in the PFC, and a
significant group difference was not observed. Overall, these results confirm neonatal Poly I:C is
successful in initiating activation of TNFα in the brain. Increases in TNFα lead to activation of
the immune system (Cope 2002), which ultimately contributes to elevated inflammation within
certain brain regions later in life (Clark et al. 2005). The increase in TNFα at least in part
validates the use of the Poly I:C rodent model of SCZ for generating neural inflammatory
abnormalities not observed in healthy/control animals.

Neonatal Poly I:C Treatment Results in Behavioral Deficits in Adolescence and Adulthood
The analyses of auditory sensorimotor gating as measured via prepulse inhibition (PPI) in
Experiments 2 and 3 revealed that neonatal Poly I:C administration resulted in deficits in
adolescence and early adulthood. These findings are consistent with past studies (Ozawa et al.
2006; Osborne et al. 2017) that showed cognitive and sensorimotor gating deficits result from
early developmental Poly I:C treatment, consistent with SCZ symptoms. Though not absolutely
equivalent to control PPI intensities, PD2024 treatment in animals administered Poly I:C were
similar to controls across all prepulse levels. This is consistent with previous work by Oh et al.
(2017) that showed an anti-inflammatory compound such as Swertisin (plant-derived Cglucosylflavone) attenuated PPI deficits in mice generated by dizocilpine (MK-801), a noncompetitive NMDA receptor antagonist.
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In addition, these behavioral findings along with an increase in TNFα protein suggest
that behavioral deficits that follow early Poly I:C treatment appear to correlate with microglial
activation in the hippocampus. These results are consistent with previous work that showed
neonatal or maternal Poly I:C administration results in structural abnormalities via reduced
hippocampal and prefrontal cortex cortical volumes in directly treated or maternally
administered Poly I:C offspring (Ribeiro 2014; Buschert et al. 2016; Meehan et al. 2017).
Mechanisms to compensate for the reduction in cortical volumes includes an elevated
neuroinflammatory response, as we show later. We did not verify changes in hippocampal
neuronal morphology in this study, but past work (Piontkewitz et al. 2012) has shown that
maternal Poly I:C treatment resulted in deficits in neurogenesis, disturbed micro-vascularization,
and elimination of parvalbumin-expressing interneurons in the hippocampus.

Neonatal Poly I:C Generates Reactive Microglia in the PFC and HPC
Analyses from Experiments 2 and 3 generally revealed neonatal administration of the
immunostimulant, Poly I:C, increases microglial cell activation in both the prefrontal cortex and
hippocampus as quantified by sampled cell body fluorescence. In Experiment 2, it was found that
Poly I:C substantially activates microglia as compared to control animals regardless of brain
region. Experiment 3 further confirmed this when higher intensities of cell body fluorescence
were found in the HPC, although the measure of overall image florescence did not reveal any
significant difference between Poly IC/Controls and the saline/control group. These results
combined indicate that Poly I:C not only increases neural TNF protein levels, but also regulates
the activation of microglial cells. These findings are consistent with the behavioral deficits in PPI
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performance observed in animals neonatally treated with the synthetic virus, again validating the
use of neonatal Poly I:C inoculation to mimic SCZ behavioral and neurological symptomatology.

Oral PD2024 Administered Through the Diet Does Not Affect Weight Gain
Administration of the TNFα modulator, PD2024, given orally through the diet did not
have an effect on body weight or weight gain over the adolescent period. This is of particular
importance regarding the treatment of SCZ with antipsychotic medications. One of the most
prominent side effects of all current antipsychotic medications is weight gain. A recent review
(Dayabandara et al. 2017) discussed the problem of dose-dependent antipsychotic-induced
weight gain, which often leads to poor compliance and eventual discontinuation. Our data
suggests a small TNFα modulator like PD2024 may be used adjunctively with an antipsychotic
and thereby reduce the effective dose without producing a change in weight gain. However, in
past work, Gabbita and colleagues have reported positive effects of PD2024 on several metabolic
parameters in animals fed a high fat diet, including cumulative food intake, insulin, body fat,
triglycerides and cholesterol (unpublished data). Although there were no effects in this particular
study with PD2024, there have been positive data on PD2024 relative to weight gain in rats fed a
high fat diet.

PD2024 Alleviates Auditory Sensorimotor Gating Deficits in Neonatal Poly I:C Animals
Auditory sensorimotor gating deficits measured using PPI were shown to be alleviated
through the use of orally available PD2024. The results from Experiment 2 showed PPI
performance improved in animals neonatally treated with Poly I:C that were later administered
PD2024. In adolescents and across all prepulse intensities, the control and Poly IC/PD2024

59

groups were equivalent and significantly different than the Poly IC/Control and Saline/PD2024
groups. This suggests PD2024 alone in as early as adolescence can improve some of the
associated cognitive symptoms that are hallmarks of SCZ. However, PD2024 generated deficits
in the controls during adolescence, but the deficits were diminished in adulthood. The
mechanisms underlying this result is not known, but suggests that PD2024 interacted at some
level with adolescent brain development. Future investigation into the mechanism and how
PD2024 created deficits in otherwise normal animals is still needed.

PD2024 Reduces Microglial Cell Activation Similar to Controls
Data obtained regarding microglial cell body activation revealed that PD2024 is effective
in reducing microglial cell activation in the HPC. Experiment 1 showed neonatal Poly I:C
elevates TNF-alpha protein levels particularly within the HPC, consistent and directly linked to
increased microglia activation. We found a significant increase in microglia activation regardless
of brain region that was reduced by PD2024 and was similar to control (Saline/Control) animals.
This suggests PD2024 successfully modulates and down-regulates neural TNFα protein
secretion, thus presumably decreasing the neuroinflammatory response produced by neonatal
Poly I:C treatment. We observed in both the PFC and HPC that microglial cell activation was
diminished by PD2024 and the remaining inflammation was comparable to what was found in
control animals. These results further suggest the ability of PD2024 to modulate TNFα protein
secretion in such a way that hinders the ability to activate microglia cells to their M1 state and
become pro-inflammatory and neurotoxic.
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Weight Gain is Decreased Following Dietary Administration of PD340
Dietary introduction of a bioavailable TNF modulator (PD340) decreases weight gain in
early adulthood. Our data demonstrated that PD340 did not affect body weight or normal weight
gain during late adolescence, but does reduce weight gain in early adulthood, especially in the
group given the higher dose of PD340 (30 mg/kg). Metabolism and distribution analyses are still
needed to explain the mechanism behind how this occurs. However, this finding is significant
and sheds valuable light for current investigations looking to reduce therapeutic doses of
antipsychotic medications in order to reduce discontinuation and not result in weight gain as is
often reported (Dayabandara et al. 2017). These results suggest PD340 could be used
adjunctively with an antipsychotic to reduce the effective dosage and decrease weight gain that is
associated with antipsychotic treatment.

PD340 Alleviates PPI Deficits in Neonatal Poly I:C Treated Rats
PPI deficits were alleviated using PD340, which was given orally through the diet.
Neonatal treatment with Poly I:C was shown to create severe deficits in adolescence that were
significantly different from controls at two of three prepulse decibel levels. At all decibel levels
(except 76 dB), PD340 alleviated sensorimotor gating deficits that resulted from neonatal Poly
I:C and performed similar to control animals. Our data suggests low dose (10 mg/kg) PD340 is
more effective for improving PPI performance at all decibel levels. This is consistent with
previous work by Long et al. (2006) that showed cannabidiol, a nonpsychoactive compound with
anti-inflammatory properties, ameliorated PPI deficits produced by MK-801 administration. We
also found that high dose (30 mg/kg) PD340 produced deficits at 76 dB in control
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(Saline/PD340) animals during adolescence, but further investigation is needed to determine if
neurotoxic effects occurred as a result of increased dosage.
In adults, neonatal Poly I:C again created PPI deficits at all auditory intensities. Our
results again suggest low dose PD340 is more effective for alleviating deficits also observed in
adulthood. The Poly IC/PD340 (10 mg/kg) group and Saline/Control groups were found to be
approximately equivalent at all decibel levels. As such, PD340 treated animals performed as well
as control animals, whereas animals neonatally administered Poly I:C had severe auditory
sensorimotor gating deficits at two distinct time periods, hallmark to SCZ development and
progression.

PD340 Increases Iba1 Immunoreactivity in the PFC
The results obtained from the Iba1 positive cell count analysis in Experiment 3 showed
PD340 increased the amount of reactive microglia cells in the prefrontal cortex, but does not
have an effect in the hippocampus. PD340 at both doses produced an increase in fluorescence
intensity regardless of neonatal intervention in the PFC. Microglial activation, additionally
measured in overall image fluorescence showed the same trend. PD340 increased fluorescence
intensity in the PFC regardless of drug treatment as compared to controls. However, in the
hippocampus, PD340 reduced fluorescence intensity as measured by sampled cell body
fluorescence and overall image fluorescence that were similar to control animals. This is
consistent with the results obtained in Experiment 2 with PD2024, suggesting the two
modulators work in a similar fashion in the HPC, but may be having differential effects in the
PFC. This is an interesting result, but we do not have any explanation as to why this may occur.
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Further investigation is needed to determine how PD340 increases microglial cell
activation in the prefrontal cortex at both low and high doses and with either saline or Poly I:C
on board. It can be hypothesized that there may be a compensatory reaction taking place where
the microglial cells in the PFC remain in a highly activated state and PD340 does not affect this
activation. Future work could use different labeling markers designed to specifically target M1
and M2 microglia to elucidate these findings. The exact mechanism for how PD340 modulates
TNF protein could also be investigated (upon patent approval) to determine if modifications
occur upstream in the pathway that eventually leads to changes in microglia.

Hippocampus Involvement in Auditory Sensorimotor Gating
Both novel TNF modulators used in this study successfully alleviated deficits in PPI
that were generated from neonatal administration of Poly I:C. PD2024 reduced microglial cell
activation in the PFC and HPC, whereas PD340 only reduced microglia activation in the HPC. In
fact, PD340 significantly increased Iba1 positive cells as well as microglia activation in the PFC.
These results in combination strongly suggest that the hippocampus plays a larger role in
mediating behavioral response measured in PPI than the PFC. This could be due to the HPC’s
role in memory formation and consolidation, thus suggesting a strong correlation between the
HPC and sensorimotor gating abilities. Future investigation using fluorescent labeling markers to
differentiate M1/M2 microglia would elucidate this claim. Characterization of microglia
morphology in the HPC could also clarify the results that we found and further strengthen this
claim.
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CHAPTER 5
CONCLUSION AND FUTURE DIRECTIONS

Evidence continues to point towards an early infection as a factor that can dysregulate the
development of the nervous system, thus increasing the possibility of developing a
neurobehavioral disorder (Meyer 2014; Flinkkilä et al. 2016). This study investigated the use of
the neonatal Poly I:C treatment, a rodent model of SCZ and the effectiveness of two novel TNFalpha modulators for improving the abnormalities generated by the model. The model proved
advantageous because behavioral abnormalities emerged in adolescence and adulthood,
consistent with clinical observation and diagnosis of SCZ.
The effects of the modulators were assessed through the use of prepulse inhibition (PPI)
to determine behavioral alterations and immunohistochemistical analysis of microglia in two
brain areas important in PPI to determine neuroinflammatory levels. Results revealed that
neonatal administration of Poly I:C activates the immune system to trigger elevated TNF-alpha
protein levels and microglial activation that persists into adulthood. Behaviorally, neonatal Poly
I:C resulted in PPI deficits, consistent with past work (Ozawa et al. 2006; Ribeiro 2014; Osborne
et al. 2017). Treatment with both novel TNF-alpha modulators were shown to alleviate
sensorimotor gating deficits in adolescence and adulthood, and decrease microglial cell
activation within distinct regions of the brain known to mediate sensorimotor gating.
Future work will continue to assess novel pro-inflammatory cytokine inhibitors and
modulators, such as those affecting TNF-alpha, and their effects on treating the many aspects of
SCZ and other neuro-related diseases/disorders. Future studies will also investigate the use of
PD2024 and PD340 used adjunctively in the Poly I:C and other rodent models of SCZ with
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antipsychotic drugs. This work will further shed light into the development, pathophysiology,
genetics, and environmental factors that contribute to developing schizophrenia. In doing so, we
will continue to learn about currently unknown aspects of SCZ and look to determine effective
treatment options for those diagnosed.
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